相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer
Sminu Bose et al.
CLINICAL BREAST CANCER (2021)
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kevin Kalinsky et al.
JAMA ONCOLOGY (2021)
Inhibitors in AKTion: ATP-competitive vs allosteric
Glorianne Lazaro et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2020)
IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
J. S. de Bono et al.
ANNALS OF ONCOLOGY (2020)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Y-J Bang et al.
EUROPEAN JOURNAL OF CANCER (2019)
Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Nico Hinz et al.
CELL COMMUNICATION AND SIGNALING (2019)
Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ERpositive/HER2-negative metastatic breast cancer previously treated with everolimus
J. R. Diamond et al.
CANCER RESEARCH (2019)
Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer
Rui Zhu et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples
Hannah L. Williams et al.
VIRCHOWS ARCHIV (2018)
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Cristina Saura et al.
CANCER DISCOVERY (2017)
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors
Rajyalakshmi Luthra et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
S-U Woo et al.
ONCOGENESIS (2017)
Pathologic Active mTOR Mutation in Brain Malformation with Intractable Epilepsy Leads to Cell-Autonomous Migration Delay
Sae Hanai et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
AKT in cancer: new molecular insights and advances in drug development
Prabhjot S. Mundi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J. Kwiatkowski et al.
CLINICAL CANCER RESEARCH (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
Jianing Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
Casey Stottrup et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Emerging Role of mTOR in the Response to Cancer Therapeutics
Erika Ilagan et al.
TRENDS IN CANCER (2016)
Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb
Mitsuko Nakashima et al.
ANNALS OF NEUROLOGY (2015)
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Moshe Elkabets et al.
CANCER CELL (2015)
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
Arindam P. Ghosh et al.
ONCOTARGET (2015)
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yi Yu et al.
PLOS ONE (2015)
Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials
F. Meric-Bernstam et al.
EUROPEAN JOURNAL OF CANCER (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Brian C. Grabiner et al.
CANCER DISCOVERY (2014)
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
Burhan Hassan et al.
ONCOTARGET (2014)
Cancer Associated E17K Mutation Causes Rapid Conformational Drift in AKT1 Pleckstrin Homology (PH) Domain
Ambuj Kumar et al.
PLOS ONE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer
Moshe Elkabets et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Starting with the ABCs: Akt in Breast Cancer
Kip A. West et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells
Mahvash Zakikhani et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
Irina N. Alimova et al.
CELL CYCLE (2009)
The life of a cell: apoptosis regulation by the PI3K/PKB pathway
Vincent Duronio
BIOCHEMICAL JOURNAL (2008)
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
Timothy A. Yap et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
分享论文
